Drug–drug interaction of microdose and regular-dose omeprazole with a CYP2C19 inhibitor and inducer

Por Park, Gab-jin, Bae, Soo Hyeon, Park, Wan-Su, Han, Seunghoon, Park, Min-Ho, Shin, Seok-Ho, Shin, Young G, Yim, Dong-Seok
Publicado no Drug Des Devel Ther (2017)

Pharmacokinetic-pharmacodynamic analysis to evaluate the effect of moxifloxacin on QT interval prolongation in healthy Korean male subjects

Por Hong, Taegon, Han, Seunghoon, Lee, Jongtae, Jeon, Sangil, Park, Gab-Jin, Park, Wan-Su, Lim, Kyoung Soo, Chung, Jae-Yong, Yu, Kyung-Sang, Yim, Dong-Seok
Publicado no Drug Des Devel Ther (2015)

Exposure–response model for sibutramine and placebo: suggestion for application to long-term weight-control drug development

Por Han, Seunghoon, Jeon, Sangil, Hong, Taegon, Lee, Jongtae, Bae, Soo Hyeon, Park, Wan-su, Park, Gab-jin, Youn, Sunil, Jang, Doo Yeon, Kim, Kyung-Soo, Yim, Dong-Seok
Publicado no Drug Des Devel Ther (2015)

Model-based adaptive phase I trial design of post-transplant decitabine maintenance in myelodysplastic syndrome

Por Han, Seunghoon, Kim, Yoo-Jin, Lee, Jongtae, Jeon, Sangil, Hong, Taegon, Park, Gab-jin, Yoon, Jae-Ho, Yahng, Seung-Ah, Shin, Seung-Hwan, Lee, Sung-Eun, Eom, Ki-Seong, Kim, Hee-Je, Min, Chang-Ki, Lee, Seok, Yim, Dong-Seok
Publicado no J Hematol Oncol (2015)